| Pharmaceutical and healthcare report, "Hormone | | | | market players covered are Pfizer, Merck & Co, |
| Replacement Therapy in Menopause - Pipeline | | | | Amgen, BioSante Pharmaceuticals, Noven |
| Assessment and Market Forecasts to 2017". The | | | | Pharmaceuticals, Bionovo, QuatRx Pharmaceuticals |
| report is an essential source of information and | | | | and Depomed. |
| analysis on the global menopause hormone therapy | | | | - Insightful review of the key industry drivers, restraints |
| market. The report identifies the key trends shaping | | | | and challenges. Each trend is independently |
| and driving the global menopause hormone therapy | | | | researched to provide a qualitative analysis of its |
| market. The report also provides insights on the | | | | implications. |
| prevalent competitive landscape and the emerging | | | | - Key topics covered include a strategic competitor |
| players expected to significantly alter the market | | | | assessment, market characterization, unmet needs |
| positioning of the existing market leaders. Most | | | | and the implications for the hormone replacement |
| importantly, the report provides valuable insights on the | | | | therapy market. |
| pipeline products within the global menopause hormone | | | | Reasons to buy |
| therapy sector. This report is built using data and | | | | The report will enhance your decision making capability. |
| information sourced from proprietary databases, | | | | It will allow you to: |
| primary and secondary research and in-house analysis | | | | - Develop and design your in-licensing and out-licensing |
| by GlobalData's team of industry experts. GlobalData | | | | strategies through a review of pipeline products and |
| estimated the global hormone therapy (HT) market to | | | | technologies and by identifying the companies with the |
| be worth $2.4 billion in 2009, indicating a Compound | | | | most robust pipelines. |
| Annual Growth Rate (CAGR) of -5.9% between 2001 | | | | - Develop business strategies by understanding the |
| and 2009. This decline in the market is mainly attributed | | | | trends shaping and driving the global menopause |
| to poor patient compliance as a result of the serious | | | | hormone therapeutics market. |
| safety concerns associated with hormones. By 2017, | | | | - Drive revenues by understanding the key trends, |
| the market is forecast to be worth $2.8 billion, with a | | | | innovative products and technologies, market |
| CAGR of 2.2% between 2009 and 2017. The market | | | | segments and companies likely to impact the global |
| is restrained by factors such as the poor acceptance | | | | menopause hormone therapeutics market in future. |
| of hormone therapies in patients and physicians. | | | | - Formulate effective sales and marketing strategies |
| Increased interest in low-dose and ultra-low dose | | | | by understanding the competitive landscape and by |
| hormone therapies are expected to lead to marginal | | | | analyzing the performance of various competitors. |
| growth of the HT market. | | | | - Identify emerging players with potentially strong |
| Scope | | | | product portfolios and create effective |
| The report provides information on the key drivers and | | | | counter-strategies to gain a competitive advantage. |
| challenges in the menopause hormone therapy market. | | | | - Organize your sales and marketing efforts by |
| Its scope includes: | | | | identifying the market categories and segments that |
| - Annualized global menopause hormone therapy | | | | present maximum opportunities for consolidations, |
| market revenues data from 2001 to 2009, forecast for | | | | investments and strategic partnerships. |
| eight years to 2017. | | | | - What's the next big thing in the global menopause |
| - Pipeline analysis data providing a split across the | | | | hormone therapy market landscape? – Identify, |
| different phases, mechanisms of action being | | | | understand and capitalize. |
| developed and emerging trends. These drugs are | | | | Companies MentionedPfizer |
| estrogens or progestins (including combination | | | | Merck & Co. |
| therapies and low-dose therapies), non-hormonal | | | | Amgen |
| products such as serum estrogen receptor | | | | BioSante Pharmaceuticals |
| modulators, serotonin reuptake inhibitors, estrogen | | | | Noven Pharmaceuticals |
| receptor alpha agonists, among others. | | | | Bionovo, Inc. |
| - Analysis of the current and future competition in the | | | | QuatRx Pharmaceuticals Company |
| global menopause hormone therapy market. The key | | | | Depomed Inc. |